See more : Biotage AB (publ) (BIOT.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Aurinia Pharmaceuticals Inc. (AUPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aurinia Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Amerigo Resources Ltd. (ARREF) Income Statement Analysis – Financial Results
- Sunflag Iron and Steel Company Limited (SUNFLAG.BO) Income Statement Analysis – Financial Results
- Orbit Garant Drilling Inc. (OBGRF) Income Statement Analysis – Financial Results
- Íslandsbanki hf. (ISB.IC) Income Statement Analysis – Financial Results
- Melcor Developments Ltd. (MRD.TO) Income Statement Analysis – Financial Results
Aurinia Pharmaceuticals Inc. (AUPH)
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 175.51M | 134.03M | 45.61M | 50.12M | 318.00K | 463.00K | 420.00K | 173.00K | 235.00K | 278.00K | 948.56K | 6.16M | 927.52K | 3.42M | 4.05M | 3.88M | 2.33M | 3.52M | 1.18M | 1.27M | 7.66M | 11.92M | 5.30M | 902.77K | 1.36M | 781.25K |
| Cost of Revenue | 14.15M | 5.66M | 1.09M | 50.33M | 52.87M | 41.38M | 1.00K | 4.00K | 12.00K | 37.00K | 939.17 | 46.24K | 185.11K | 50.99K | 575.88K | 2.12M | 1.05M | 597.12K | 0.00 | 0.00 | 0.00 | 686.01K | 1.03M | 680.66K | 679.10K | 520.83K |
| Gross Profit | 161.37M | 128.37M | 44.51M | -209.00K | -52.55M | -40.92M | 419.00K | 169.00K | 223.00K | 241.00K | 947.62K | 6.11M | 742.41K | 3.37M | 3.48M | 1.76M | 1.28M | 2.93M | 1.18M | 1.27M | 7.66M | 11.23M | 4.27M | 222.11K | 679.10K | 260.42K |
| Gross Profit Ratio | 91.94% | 95.77% | 97.61% | -0.42% | -16,524.53% | -8,837.80% | 99.76% | 97.69% | 94.89% | 86.69% | 99.90% | 99.25% | 80.04% | 98.51% | 85.79% | 45.44% | 55.02% | 83.05% | 100.00% | 100.00% | 100.00% | 94.24% | 80.65% | 24.60% | 50.00% | 33.33% |
| Research & Development | 49.64M | 44.99M | 51.14M | 50.33M | 52.87M | 41.38M | 33.93M | 14.53M | 15.98M | 9.11M | 1.93M | 5.51M | 3.48M | 3.99M | 7.65M | 11.44M | 29.70M | 19.00M | 19.45M | 13.52M | 9.12M | 7.11M | 8.41M | 4.78M | 1.43M | 1.43M |
| General & Administrative | 195.04M | 196.37M | 171.44M | 95.98M | 22.15M | 13.67M | 12.10M | 6.97M | 6.26M | 6.89M | 2.23M | 3.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 195.04M | 196.37M | 171.44M | 95.98M | 22.15M | 13.67M | 12.10M | 6.97M | 6.26M | 6.89M | 2.23M | 3.90M | 2.74M | 3.27M | 3.61M | 4.54M | 5.71M | 6.19M | 9.78M | 7.85M | 8.33M | 4.97M | 3.05M | 1.77M | 1.02M | 1.37M |
| Other Expenses | 8.38M | -1.52M | 2.67M | 1.29M | 1.55M | 2.07M | 195.00K | -1.63M | -337.00K | -848.00K | -4.21M | 2.17M | 4.02M | -424.93K | 2.45M | 478.23K | 1.90M | 1.88M | 2.24M | 3.06M | 1.42M | 701.89K | 338.57K | 411.00K | -543.28K | 130.21K |
| Operating Expenses | 253.06M | 239.84M | 225.25M | 147.60M | 76.57M | 56.62M | 47.48M | 22.98M | 23.80M | 17.52M | 4.98M | 11.58M | 7.18M | 8.42M | 12.49M | 17.38M | 37.31M | 27.08M | 31.47M | 24.43M | 18.88M | 12.77M | 11.80M | 6.96M | 1.90M | 2.93M |
| Cost & Expenses | 267.20M | 245.50M | 226.34M | 147.60M | 76.57M | 56.62M | 47.48M | 22.99M | 23.82M | 17.56M | 4.98M | 11.63M | 7.37M | 8.47M | 13.07M | 19.50M | 38.36M | 27.68M | 31.47M | 24.43M | 18.88M | 13.46M | 12.83M | 7.64M | 2.58M | 3.45M |
| Interest Income | 17.00M | 5.12M | 529.00K | 1.52M | 2.70M | 2.23M | 1.04M | 27.00K | 50.00K | 65.00K | 2.82K | 7.04K | 9.79K | 12.00K | 38.20K | 661.58K | -0.30 | -0.23 | -0.20 | 0.00 | -0.60 | 0.00 | 0.00 | 478.74K | 0.00 | 0.00 |
| Interest Expense | 2.78M | 5.12M | 0.00 | 0.00 | 39.00K | 2.23M | 702.00K | 27.00K | 50.00K | 30.00K | 100.49K | 56.29K | 979.43 | 12.00K | 1.03M | 845.25K | 141.37K | 268.53K | 381.44K | 0.00 | 34.70K | 0.00 | 0.00 | 14.98K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.65M | 2.71M | 2.76M | 1.37M | 1.17M | 1.57M | 1.46M | 1.48M | 1.56M | 1.52M | 813.32K | 851.40K | 960.82K | 1.15M | 1.27M | 1.40M | 1.42M | -867.36K | 1.97M | 2.25M | 1.34M | 680.93K | 331.03K | 411.00K | 203.73K | 260.42K |
| EBITDA | -63.05M | -103.65M | -177.45M | -102.92M | -89.77M | -53.93M | -45.61M | -21.34M | -22.02M | -15.70M | -5.86M | -8.94M | -1.69M | -4.26M | -5.20M | -14.22M | -34.12M | -22.60M | -28.15M | -20.83M | -9.83M | -861.96K | -7.20M | -6.33M | -1.09M | -1.95M |
| EBITDA Ratio | -35.92% | -83.17% | -391.70% | -191.93% | -25,468.87% | -9,641.25% | -5,162.62% | -12,038.73% | -11,465.96% | -5,646.04% | -338.91% | -75.60% | -155.86% | -126.07% | -191.07% | -366.72% | -1,467.52% | -641.62% | -2,390.13% | -1,635.73% | -128.29% | -7.23% | -135.89% | -701.08% | -75.00% | -308.33% |
| Operating Income | -91.69M | -111.47M | -180.74M | -104.29M | -82.54M | -56.16M | -47.06M | -22.81M | -23.58M | -17.28M | -5.51M | -5.47M | -6.44M | -5.05M | -10.05M | -16.36M | -36.02M | -24.15M | -30.29M | -23.16M | -11.22M | -1.54M | -7.53M | -6.74M | -1.22M | -2.67M |
| Operating Income Ratio | -52.24% | -83.17% | -396.31% | -208.09% | -25,955.66% | -12,129.16% | -11,205.48% | -13,187.28% | -10,034.04% | -6,216.55% | -580.40% | -88.80% | -694.19% | -147.53% | -247.91% | -422.00% | -1,543.04% | -685.66% | -2,571.49% | -1,818.42% | -146.41% | -12.95% | -142.14% | -746.61% | -90.00% | -341.67% |
| Total Other Income/Expenses | 14.22M | 5.12M | 529.00K | 1.52M | 2.70M | 2.23M | -23.73M | -481.00K | 4.97M | -2.14M | -1.07M | -4.27M | 3.90M | -412.93K | 2.45M | -1.75M | 2.20M | 1.30M | 1.21M | 602.26K | -3.30M | 1.25M | 180.28K | 468.97K | 0.00 | 325.52K |
| Income Before Tax | -77.47M | -106.35M | -180.21M | -102.77M | -123.70M | -64.05M | -70.79M | -23.30M | -18.61M | -16.65M | -6.40M | -9.74M | -2.41M | -5.46M | -7.60M | -15.88M | -33.82M | -22.85M | -29.07M | -22.56M | -14.52M | -294.10K | -7.35M | -6.27M | 0.00 | -2.34M |
| Income Before Tax Ratio | -44.14% | -79.35% | -395.15% | -205.06% | -38,900.00% | -13,833.05% | -16,855.24% | -13,465.32% | -7,917.87% | -5,988.13% | -674.95% | -158.15% | -259.56% | -159.60% | -187.51% | -409.67% | -1,448.70% | -648.76% | -2,468.35% | -1,771.13% | -189.52% | -2.47% | -138.74% | -694.66% | 0.00% | -300.00% |
| Income Tax Expense | 551.00K | 1.83M | 760.00K | -94.00K | 144.00K | 73.00K | 23.92M | 481.00K | -4.97M | 30.00K | -3.86M | 55.29K | 4.02M | 100.98K | 1.03M | 741.17K | 350.40K | -857.93 | 861.03 | 3.33K | 126.47K | 71.78K | 55.28K | 13.68K | 0.00 | -130.21K |
| Net Income | -78.02M | -108.18M | -180.97M | -102.68M | -123.85M | -64.12M | -70.79M | -23.30M | -18.61M | -16.65M | -2.55M | -9.74M | -2.41M | -3.66M | -7.60M | -15.88M | -33.82M | -22.85M | -29.08M | -22.56M | -14.65M | -365.87K | -7.40M | -6.28M | -1.22M | -2.21M |
| Net Income Ratio | -44.45% | -80.71% | -396.81% | -204.88% | -38,945.28% | -13,848.81% | -16,855.24% | -13,465.32% | -7,917.87% | -5,988.13% | -268.42% | -158.13% | -259.56% | -107.02% | -187.51% | -409.67% | -1,448.70% | -648.73% | -2,468.42% | -1,771.39% | -191.17% | -3.07% | -139.78% | -696.18% | -90.00% | -283.33% |
| EPS | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 | -0.76 | -0.92 | -0.66 | -0.58 | -0.57 | -0.40 | -2.74 | -0.70 | -1.44 | -3.17 | -7.47 | -16.34 | -13.73 | -18.51 | -14.97 | -10.41 | -0.32 | -7.22 | -8.39 | -2.25 | -4.56 |
| EPS Diluted | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 | -0.76 | -0.92 | -0.66 | -0.58 | -0.57 | -0.40 | -2.74 | -0.70 | -1.44 | -3.17 | -7.47 | -16.34 | -13.56 | -18.39 | -14.96 | -10.41 | -0.28 | -7.22 | -8.39 | -2.25 | -4.56 |
| Weighted Avg Shares Out | 143.24M | 141.92M | 129.37M | 118.47M | 93.02M | 84.78M | 76.92M | 35.29M | 32.15M | 28.99M | 6.34M | 3.55M | 3.46M | 2.55M | 2.39M | 2.12M | 2.07M | 1.66M | 1.57M | 1.51M | 1.41M | 1.15M | 1.03M | 749.00K | 542.95K | 485.71K |
| Weighted Avg Shares Out (Dil) | 143.24M | 141.92M | 129.37M | 118.47M | 93.02M | 84.78M | 76.95M | 35.29M | 32.15M | 29.16M | 6.34M | 3.55M | 3.46M | 2.55M | 2.39M | 2.12M | 2.07M | 1.69M | 1.58M | 1.51M | 1.41M | 1.29M | 1.03M | 749.00K | 542.95K | 485.71K |
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The...
Aurinia to Participate in Jefferies London Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies London Healthcare Conference.
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become...
Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe...
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago.
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth.
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months ended September 30, 2024. With continued strong commercial execution, the Company achieved significant year-over-year...
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024.
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at ASN Kidney Week 2024.
Source: https://incomestatements.info
Category: Stock Reports